Human TRAIL R3/TNFRSF10C Antibody Summary
Ala26-Ala221
Accession # O14798
Applications
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Scientific Data
TRAIL R3/TNFRSF10C Inhibition of TRAIL/TNFSF10-induced Cytotoxicity and Neutralization by Human TRAIL R3/TNFRSF10C Antibody. In the presence of the metabolic inhibitor actinomycin D (1 µg/mL), Recombinant Human TRAIL R3/TNFRSF10C Fc Chimera (Catalog # 630-TR) inhibits Recombinant Human TRAIL/TNFSF10 (Catalog # 375-TEC) induced cytotoxicity in the L-929 mouse fibroblast cell line in a dose-dependent manner (orange line). Under these conditions, inhibition of Recombinant Human TRAIL/TNFSF10 (20 ng/mL) activity elicited by Recombinant Human TRAIL R3/TNFRSF10C Fc Chimera (10 ng/mL) is neutralized (green line) by increasing concentrations of Human TRAIL R3/TNFRSF10C Monoclonal Antibody (Catalog # MAB630). The ND50 is typically 0.02-0.08 µg/mL.
Reconstitution Calculator
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: TRAIL R3/TNFRSF10C
TRAIL R3, also called TNFRSF10C, DcR1 (decoy receptor 1), LIT, and TRID, is a glycosylphosphatidylinositol-linked membrane protein which binds TRAIL (Apo2 Ligand) with high affinity (1, 2). TRAIL R3 contains a TRAIL-binding extracellular cysteine-rich domain but lacks an intracellular signaling domain. As a result, binding of TRAIL to TRAIL R3 does not trigger a pro-apoptotic signal. TRAIL R3 has been shown to protect cells bearing TRAIL R1 and/or TRAIL R2 from TRAIL-induced apoptosis.
Product Datasheets
Citation for Human TRAIL R3/TNFRSF10C Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
1 Citation: Showing 1 - 1
-
TRAIL Receptor Targeting Agents Potentiate PARP Inhibitor Efficacy in Pancreatic Cancer Independently of BRCA2 Mutation Status
Authors: Najib Ben Khaled, Katharina Hammer, Liangtao Ye, Ahmed Alnatsha, Sebastian A. Widholz, Ignazio Piseddu et al.
Cancers (Basel)
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsReviews for Human TRAIL R3/TNFRSF10C Antibody
There are currently no reviews for this product. Be the first to review Human TRAIL R3/TNFRSF10C Antibody and earn rewards!
Have you used Human TRAIL R3/TNFRSF10C Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image